Brainsway (NASDAQ:BWAY) Stock Rating Upgraded by Wall Street Zen

Brainsway (NASDAQ:BWAY) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report issued on Sunday.

BWAY has been the topic of a number of other research reports. Zacks Research upgraded Brainsway from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 13th. New Street Research reaffirmed a “buy” rating on shares of Brainsway in a research report on Friday, July 24th. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price target on shares of Brainsway in a report on Friday, July 17th. BTIG Research assumed coverage on shares of Brainsway in a report on Monday, July 20th. They set a “buy” rating and a $18.00 price objective on the stock. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of Brainsway in a research report on Tuesday, July 21st. One research analyst has rated the stock with a Strong Buy rating and five have assigned a Buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $15.67.

Brainsway Trading Up 3.8%

Shares of Brainsway stock opened at $15.81 on Friday. The company has a market capitalization of $634.46 million, a P/E ratio of 45.17 and a beta of 1.24. The stock has a fifty day simple moving average of $15.05 and a 200 day simple moving average of $14.13. Brainsway has a 12-month low of $5.70 and a 12-month high of $17.35.

Brainsway (NASDAQ:BWAY) last issued its quarterly earnings data on Wednesday, May 13th. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.05 by $0.07. Brainsway had a return on equity of 12.28% and a net margin of 15.68%.The business had revenue of $15.53 million for the quarter, compared to analysts’ expectations of $14.63 million. On average, analysts predict that Brainsway will post 0.33 EPS for the current year.

Institutional Investors Weigh In On Brainsway

Several institutional investors have recently bought and sold shares of BWAY. Masters Capital Management LLC grew its position in Brainsway by 65.0% during the 1st quarter. Masters Capital Management LLC now owns 1,650,000 shares of the company’s stock worth $21,928,000 after acquiring an additional 650,000 shares during the last quarter. Renaissance Technologies LLC lifted its position in Brainsway by 87.2% in the first quarter. Renaissance Technologies LLC now owns 518,420 shares of the company’s stock valued at $6,890,000 after purchasing an additional 241,560 shares during the last quarter. Y.D. More Investments Ltd boosted its stake in shares of Brainsway by 136.6% during the first quarter. Y.D. More Investments Ltd now owns 272,004 shares of the company’s stock valued at $3,615,000 after purchasing an additional 157,042 shares during the period. Sei Investments Co. boosted its stake in shares of Brainsway by 262.5% during the first quarter. Sei Investments Co. now owns 226,378 shares of the company’s stock valued at $3,009,000 after purchasing an additional 163,925 shares during the period. Finally, ARK Investment Management LLC bought a new position in shares of Brainsway in the fourth quarter worth approximately $2,422,000. 30.11% of the stock is currently owned by hedge funds and other institutional investors.

Brainsway Company Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.